Cargando…
COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817400/ https://www.ncbi.nlm.nih.gov/pubmed/33517176 http://dx.doi.org/10.1016/j.msard.2021.102775 |
| _version_ | 1783638628831854592 |
|---|---|
| author | Gelibter, Stefano Orrico, Mario Filippi, Massimo Moiola, Lucia |
| author_facet | Gelibter, Stefano Orrico, Mario Filippi, Massimo Moiola, Lucia |
| author_sort | Gelibter, Stefano |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7817400 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78174002021-01-21 COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program? Gelibter, Stefano Orrico, Mario Filippi, Massimo Moiola, Lucia Mult Scler Relat Disord Correspondence Elsevier B.V. 2021-04 2021-01-19 /pmc/articles/PMC7817400/ /pubmed/33517176 http://dx.doi.org/10.1016/j.msard.2021.102775 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Gelibter, Stefano Orrico, Mario Filippi, Massimo Moiola, Lucia COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program? |
| title | COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program? |
| title_full | COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program? |
| title_fullStr | COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program? |
| title_full_unstemmed | COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program? |
| title_short | COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program? |
| title_sort | covid-19 with no antibody response in a multiple sclerosis patient treated with cladribine: implication for vaccination program? |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817400/ https://www.ncbi.nlm.nih.gov/pubmed/33517176 http://dx.doi.org/10.1016/j.msard.2021.102775 |
| work_keys_str_mv | AT gelibterstefano covid19withnoantibodyresponseinamultiplesclerosispatienttreatedwithcladribineimplicationforvaccinationprogram AT orricomario covid19withnoantibodyresponseinamultiplesclerosispatienttreatedwithcladribineimplicationforvaccinationprogram AT filippimassimo covid19withnoantibodyresponseinamultiplesclerosispatienttreatedwithcladribineimplicationforvaccinationprogram AT moiolalucia covid19withnoantibodyresponseinamultiplesclerosispatienttreatedwithcladribineimplicationforvaccinationprogram |